The case centered on whether Alnylam’s patents, U.S. Patent Nos. 11,246,933 and 11,382,979 were infringed by Moderna’s use of SM-102-a cationic lipid in Moderna’s COVID-19 vaccine formulations.

SK bioscience filed a nullity suit in 2023 challenging Moderna's patent on modified nucleosides, nucleotides and nucleic acids, as well as their uses, the company said in a press release.

Moderna Inc. gained US approval for a new Covid vaccine for a narrower group of people, in the latest sign that regulators are restricting access to immunizations under the leadership of Health ...

Biotech company Alnylam Pharmaceuticals conceded defeat for now in a lawsuit against Pfizer and BioNTech over technology in their COVID-19 vaccine, asking a Delaware federal court on Tuesday to ...

Moderna (MRNA) stock in focus as the U.S. FDA approved its next-gen COVID-19 vaccine, mNEXSPIKE,. Read more here.

The FDA has approved Moderna’s new Covid-19 vaccine, though it placed restrictions on its use that the company’s existing Covid shot does not currently face.

Moderna Inc. has agreed to do a placebo-controlled trial of its new Covid vaccine that was recently approved by US regulators, Health and Human Services Secretary Robert F. Kennedy Jr. said Tuesday.

Moderna Inc. said it has “voluntarily” withdrawn its application for regulatory approval for its combination COVID and flu shot for people 50 and over, a setback for the company.

Moderna's study, involving 8,000 adults 50 and older, showed the new combo shot generated an immune response against COVID and most strains of flu compared to existing stand-alone shots.

Moderna’s combined Covid and flu shot outperformed the existing standalone vaccines for both viruses, according to the results of a phase 3 clinical trial published Wednesday in the Journal of ...

SK bioscience-Moderna patent suit SEOUL, April 23 (Yonhap) -- SK bioscience Co., the biopharmaceutical arm of South Korea's SK Group, said Wednesday it has achieved a "final victory" in a patent ...